SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.co ...

Core Viewpoint - Defence Therapeutics Inc. is enhancing its collaboration with Canadian Nuclear Laboratories to accelerate its radiopharmaceutical program, which is a key part of its strategy to develop effective cancer therapies [1][5]. Group 1: Collaboration and Program Development - Defence has been working with CNL on an Accum®-enhanced radio-immunoconjugate program, which is nearing a critical stage for candidate selection and preparation for first-in-human clinical studies [2]. - The collaboration is expanding to include multiple other radioisotope programs utilizing Defence's proprietary Accum®, allowing for rapid expansion of its radiopharmaceutical portfolio [3]. Group 2: Technology and Efficacy - Radiopharmaceutical therapies require precise intracellular and nuclear localization to maximize efficacy, which Defence's Accum® platform facilitates by enabling active transport to the cell nucleus [4]. - This technology aims to enhance the potency of targeted radiotherapies while reducing toxicity, thereby improving treatment outcomes for cancer patients [4]. Group 3: Strategic Importance - The collaboration with CNL is described as a cornerstone of Defence's radiopharmaceutical strategy, positioning it alongside the company's antibody-drug conjugate (ADC) program as a top development priority [5]. - The partnership leverages CNL's nuclear science expertise to advance Defence's proprietary pipeline in radiopharmaceuticals, aiming to transform advanced biologics into safer, more effective cancer therapies [5].

Core Viewpoint - Perspective Therapeutics, Inc. announced updated interim results from its Phase 1/2a clinical trial of [Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors, presented at the 2026 ASCO Gastrointestinal Cancers Symposium [1] Clinical Trial Results - The interim results are based on a data cut-off date of December 10, 2025, including safety data from 56 patients across three dose cohorts and efficacy analysis from two patients in Cohort 1 and 23 patients in Cohort 2 [2] - Updated interim results show that [Pb]VMT-α-NET continues to be well-tolerated with no reports of dose limiting toxicities (DLTs) or serious treatment-related complications [6][7] - Objective response rate in Cohort 2 is 39%, with 9 patients showing response according to RECIST v1.1, including 8 previously confirmed responders [6][7] Safety Profile - Among the 56 patients analyzed for safety, 21 patients (37.5%) experienced Grade 3 or higher treatment-emergent adverse events, with one transient Grade 4 event reported [7] - Serious adverse events were reported in five patients, none of which were deemed related to the study medication [7] Efficacy Insights - The updated efficacy analysis suggests durable disease control and deepening of tumor response in the first 23 patients of Cohort 2 and both patients in Cohort 1 [6] - 19 of the 25 patients (76%) from the previous ESMO presentation were without progression and remained alive, including both patients in Cohort 1 [7] Future Plans - The company plans to submit additional efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 to more medical conferences in 2026, along with regulatory engagement [6][9] - The Chief Medical Officer emphasized the compelling clinical profile of VMT-α-NET and the completion of DLT assessment for the higher dose cohort, allowing for the enrollment of more patients [8]